Stevens-Johnson syndrome complications include:
April 22, 2014
- Secondary skin infection (cellulitis). Cellulitis can lead to life-threatening complications, including sepsis.
- Blood infection (sepsis). Sepsis occurs when bacteria from an infection enter your bloodstream and spread throughout your body. Sepsis is a rapidly progressing, life-threatening condition that can cause shock and organ failure.
- Eye problems. The rash caused by Stevens-Johnson syndrome can lead to inflammation in your eyes. In mild cases, this may cause irritation and dry eyes. In severe cases, it can lead to extensive tissue damage and scarring that results in blindness.
- Damage to internal organs. It's unusual for this condition to affect internal organs. But it may cause inflammation of the lungs, heart, kidneys or liver.
- Permanent skin damage. When your skin grows back following Stevens-Johnson syndrome, it may have abnormal bumps and coloring. And you may have scars. Lasting skin problems may cause your hair to fall out, and your fingernails and toenails may not grow normally.
- Nirken MH, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis. http://www.uptodate.com/home. Accessed Nov. 25, 2013.
- High WA, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae. http://www.uptodate.com/home. Accessed Nov. 25, 2013.
- Ferri FF. Ferri's Clinical Advisor 2014: 5 Books in 1. Philadelphia, Pa.: Mosby Elsevier; 2014. https://www.clinicalkey.com. Accessed Nov. 25, 2013.
- Lebwohl MG, et al. Treatment of Skin Disease: Comprehensive Therapeutic Strategies. 4th ed. Philadelphia, Pa.: Saunders Elsevier; 2014. https://www.clinicalkey.com. Accessed Nov. 25, 2013.
- AskMayoExpert. Nonimmunoglobulin e-mediated (non-IgE) drug sensitivity. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2012.
- Wetter DA, et al. Clinical, etiologic and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clinic Proceedings. 2010;85:131.
- Bolognia JL, et al. Dermatology. 3rd ed. Philadelphia, Pa: Saunders Elsevier; 2012. https://www.clinicalkey.com. Accessed Nov. 25, 2013.
- Tangamornsuksan W, et al. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis. JAMA Dermatology. 2013;149:1025.
- FDA drug safety communication: FDA warns of rare but serious skin reactions with the pain reliever/fever reducer acetaminophen. U.S. Food and Drug Administration. http://www.fda.gov/drugs/drugsafety/ucm363041.htm. Accessed Nov. 25, 2013.
- Yip VL, et al. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: A systematic review. Clinical Pharmacology and Therapeutics. 2012;92:757.
- Goldsmith LA, et al., eds. Fitzpatrick's Dermatology in General Medicine. 8th ed. New York, N.Y.: The McGraw-Hill Companies; 2012. http://www.accessmedicine.com/resourceTOC.aspx?resourceID=740. Accessed Nov. 25, 2013.
- Gerull R, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: A review. Critical Care Medicine. 2011;39:1521.
- Ferrandiz-Pulido C, et al. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Archives of Disease in Childhood. 2013;98:998.